# A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

> **NCT04481763** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jiangxi Provincial Cancer Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Camrelizumab
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT04481763
- **Lead sponsor:** Jiangxi Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-14
- **Primary completion:** 2024-08-30
- **Final completion:** 2026-10-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04481763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04481763, "A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04481763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*